Oxford SimCell Limited – The BMC Project

Oxford SimCell is one of the accelerator companies that iiCON has continued to work with. They have secured a Biomedical Catalyst (BMC) award, with the Liverpool School of Tropical Medicine (LSTM) being collaborators.

Oxford SimCell is a spin-out from the University of Oxford that is developing vaccines using a novel technology approach. The BMC project is utilising peripheral blood mononuclear cell models developed by LSTM to evaluate the immunogenicity of the SimCell vaccine candidate.

This will provide an evaluation of the in vitro effectiveness of a new formulation of the SimCell vaccine, which has a longer shelf life and can be stored at room temperature.

This work is paving the way for the development of a vaccine suitable for global use, which is effective against Pseudomonas aeruginosa – a World Health Organisation (WHO) priority 1 pathogen that is responsible for over 500,000 deaths per year globally, of which over 300,000 are associated with antimicrobial resistance.

“Our collaboration with LSTM, supported by the biomedical catalyst award, is a testament to the strength of our partnerships. We also value the continued support from iiCON, whose role in facilitating this project has been crucial. Together, we are advancing our Simcell vaccine technology to address the urgent need for effective solutions against multi-drug resistant pseudomonas aeruginosa. This project exemplifies how innovative partnerships can drive significant progress in global health, especially in regions where such advancements are most needed.” Chia-Chen (Jane) Hsu, COO of Oxford SimCell Limited